Skip to content
Sandoz
-
Sandoz expands biosimilar pipeline with mAbxience deal for haemophilia A treatment
The agreement covers licensing, development, manufacturing and commercialisation of the candidate, which is currently in the early stages of development.
-
Sandoz expands commercialization pipeline to 39 assets through US$322M Henlius partnership
Under the milestone-based agreement, Sandoz could pay Henlius up to US$322 million, including near-term payments of up to US$100.5 million linked to the initial assets.
-
Sandoz inks global deal for Samsung Bioepis’ Vedolizumab biosimilar
This deal builds on the existing partnership between the two companies and could expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets.